| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Vignesh K Nagesh, Hadrian Hoang-Vu Tran, Daniel Elias, Izage Kianifar Aguilar, Tanni Sethi, Aiswarya Menon, Charlene Mansour, Florchi Furman, Kylie Tsotsos, Talia Subar, Auda Auda, Aman Sidiqui, Jevon Lamar, Nikita Wadhwani, Shraboni Dey, Abraham Lo, Adam Atoot, Simcha Weissman, Humberto Sifuentes and Ayrton I Bangolo |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Vignesh K Nagesh, MBBS, MD, Doctor, Department of Internal Medicine, Hackensack Palisades Medical Center, 7600 River Road, North Bergen, NJ 07047, United States. vgneshkrishnan@gmail.com |
| Key Words |
Clostridium difficile; Antibiotics; Vancomycin; Fidaxomicin; Prevention; Bezlotoxumab; Fecal microbiota transplant |
| Core Tip |
Clostridium difficile infections (CDIs) are one of the most common hospitals acquired infections and are caused by use of antibiotics. The treatment is limited to 3 antibiotics currently. There has been a rise in recurrent CDIs. Our review aims to provide an overview of current testing and treatment modalities, prevention, new treatment options, challenges and current studies in the aspect of CDIs, which has become a growing concern to global health. |
| Publish Date |
2024-09-03 08:54 |
| Citation |
<p>Nagesh VK, Tran HHV, Elias D, Kianifar Aguilar I, Sethi T, Menon A, Mansour C, Furman F, Tsotsos K, Subar T, Auda A, Sidiqui A, Lamar J, Wadhwani N, Dey S, Lo A, Atoot A, Weissman S, Sifuentes H, Bangolo AI. Therapeutics involved in managing initial and recurrent Clostridium difficile infection: An updated literature review. <i>World J Gastrointest Pharmacol Ther</i> 2024; 15(5): 95467</p> |
| URL |
https://www.wjgnet.com/2150-5349/full/v15/i5/95467.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v15.i5.95467 |
